Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR OTCMKTS:JUSHF NASDAQ:PRTC NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$5.35+8.1%$5.30$1.67▼$7.29$524.23M0.944.96 million shs6.03 million shsJUSHFJushi$0.67+1.6%$0.47$0.22▼$0.98$132.65M-0.98724,852 shs105,591 shsPRTCPureTech Health$18.71+1.7%$18.21$13.30▼$25.00$458.51M1.122,914 shs1,806 shsSLDBSolid Biosciences$5.93+4.8%$5.74$2.41▼$10.07$461.76M2.441.16 million shs794,407 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma0.00%+9.18%-3.60%+42.67%+184.57%JUSHFJushi0.00%+14.62%+43.58%+117.55%+14.87%PRTCPureTech Health0.00%-0.69%-0.72%+2.80%-13.19%SLDBSolid Biosciences0.00%-2.95%-11.23%+111.03%-40.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRaTyr Pharma2.5258 of 5 stars3.61.00.00.03.31.70.6JUSHFJushi1.8084 of 5 stars0.05.00.00.03.01.70.6PRTCPureTech Health2.8161 of 5 stars3.85.00.00.02.80.00.0SLDBSolid Biosciences3.4075 of 5 stars4.62.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 3.17Buy$23.25334.58% UpsideJUSHFJushi 1.00SellN/AN/APRTCPureTech Health 3.50Strong Buy$45.00140.51% UpsideSLDBSolid Biosciences 3.17Buy$15.00152.95% UpsideCurrent Analyst Ratings BreakdownLatest JUSHF, ATYR, PRTC, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025ATYRaTyr PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $17.008/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $13.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $14.007/21/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$16.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/20/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025SLDBSolid BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.006/4/2025ATYRaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr Pharma$230K2,279.33N/AN/A$0.76 per share7.04JUSHFJushi$257.52M0.52N/AN/A($0.40) per share-1.69PRTCPureTech Health$4.32M104.64$2.35 per share7.97$17.04 per share1.10SLDBSolid Biosciences$8.09M57.08N/AN/A$3.32 per share1.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)JUSHFJushi-$48.78M-$0.29N/AN/AN/A-22.56%N/A-13.23%11/6/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)Latest JUSHF, ATYR, PRTC, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/A8/7/2025Q2 2025ATYRaTyr Pharma-$0.18-$0.22-$0.04-$0.22N/AN/A8/5/2025Q2 2025JUSHFJushi-$0.06-$0.06N/A-$0.06$64.67 million$65.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/AJUSHFJushiN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr Pharma0.015.635.63JUSHFJushiN/A1.020.48PRTCPureTech HealthN/A9.339.33SLDBSolid BiosciencesN/A9.349.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%JUSHFJushi21.68%PRTCPureTech Health0.04%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipATYRaTyr Pharma3.70%JUSHFJushi22.48%PRTCPureTech Health5.30%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5397.99 million94.36 millionOptionableJUSHFJushi1,234196.70 million152.48 millionNot OptionablePRTCPureTech Health10024.13 million22.85 millionNot OptionableSLDBSolid Biosciences10077.87 million76.39 millionOptionableJUSHF, ATYR, PRTC, and SLDB HeadlinesRecent News About These CompaniesMonashee Investment Management LLC Grows Position in Solid Biosciences Inc. $SLDBAugust 23 at 8:31 AM | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for SLDB EarningsAugust 19, 2025 | marketbeat.comQ3 EPS Forecast for Solid Biosciences Increased by AnalystAugust 19, 2025 | americanbankingnews.comQ1 Earnings Forecast for SLDB Issued By Leerink PartnrsAugust 17, 2025 | marketbeat.comFY2025 EPS Estimate for Solid Biosciences Boosted by AnalystAugust 17, 2025 | marketbeat.comHC Wainwright Forecasts Lower Earnings for Solid BiosciencesAugust 17, 2025 | marketbeat.comQ3 Earnings Estimate for Solid Biosciences Issued By WedbushAugust 17, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Solid Biosciences (NASDAQ:SLDB) Price Target to $13.00August 17, 2025 | americanbankingnews.comLeerink Partnrs Weighs in on SLDB Q1 EarningsAugust 17, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street ZenAugust 17, 2025 | marketbeat.comSolid Biosciences' (SLDB) "Buy" Rating Reiterated at Chardan CapitalAugust 17, 2025 | americanbankingnews.comHC Wainwright Brokers Reduce Earnings Estimates for SLDBAugust 17, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Given "Buy" Rating at Chardan CapitalAugust 16, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Price Target Lowered to $13.00 at JPMorgan Chase & Co.August 16, 2025 | marketbeat.comHC Wainwright Predicts Lower Earnings for Solid BiosciencesAugust 16, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Shares Up 9.9% Following Better-Than-Expected EarningsAugust 15, 2025 | marketbeat.comWedbush Lowers Solid Biosciences (NASDAQ:SLDB) Price Target to $14.00August 15, 2025 | marketbeat.com40,930 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Purchased by XTX Topco LtdAugust 15, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Trading 9.9% Higher on Strong EarningsAugust 15, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.09 EPSAugust 14, 2025 | marketbeat.comSolid Biosciences Inc.: Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 13, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJUSHF, ATYR, PRTC, and SLDB Company DescriptionsaTyr Pharma NASDAQ:ATYR$5.35 +0.40 (+8.08%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.38 +0.03 (+0.47%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Jushi OTCMKTS:JUSHF$0.67 +0.01 (+1.58%) As of 08/22/2025 03:59 PM EasternJushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.PureTech Health NASDAQ:PRTC$18.71 +0.31 (+1.68%) Closing price 08/22/2025 03:54 PM EasternExtended Trading$18.71 0.00 (0.00%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Solid Biosciences NASDAQ:SLDB$5.93 +0.27 (+4.77%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.90 -0.03 (-0.57%) As of 08/22/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.